Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28‐Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels

Documenti analoghi

• Complementary Analysis of Local and Systemic Effects of Dupilumab in Paediatric AD Using Tape Strips and Serum
  di: Lisa P. van der Rijst, et al.
  Pubblicazione: (2025)
• Addressing potential bias when assessing safety of biologics and JAK inhibitors in atopic dermatitis
  di: Lian F. van der Gang, et al.
  Pubblicazione: (2026)
• Translating 6‐year trial safety data of upadacitinib in atopic dermatitis into clinical practice
  di: Lian F. van der Gang, et al.
  Pubblicazione: (2026)
• Dupilumab‐Associated Ocular Surface Disease in Paediatric Atopic Dermatitis Patients: Results From the BioDay Registry
  di: Lisa P. van der Rijst, et al.
  Pubblicazione: (2025)
• Dupilumab induces a significant decrease of food specific immunoglobulin E levels in pediatric atopic dermatitis patients
  di: Lisa P. van der Rijst, et al.
  Pubblicazione: (2024)